Is Apoquel Safe for Dogs Long-Term?

Apoquel (oclacitinib maleate) is one of the most widely prescribed allergy medications in veterinary medicine in the United States. FDA-approved in 2013 by Zoetis, it controls pruritus (severe itching) associated with allergic dermatitis and controls atopic dermatitis in dogs aged 12 months and older. It works by selectively inhibiting JAK1 (Janus kinase 1) — the enzyme pathway that drives itch and allergic inflammation — rather than broadly suppressing the immune system like steroids do. A 2025 peer-reviewed pharmacovigilance study published in PMC (Nederveld, Krautmann, Mitchell) reviewed over a decade of post-market safety data and found the adverse event profile consistent with pre-approval studies. However, the FDA-approved label carries explicit warnings about susceptibility to infection and exacerbation of neoplastic (cancer) conditions that every owner should understand. Here are the 10 most important facts.

• 1
  Is Apoquel safe for dogs long-term? Yes for most dogs — Zoetis reports 60% of moderate-to-severe atopic dermatitis cases are controlled long-term at once-daily dosing · Low likelihood of GI side effects · Rare serious side effects with long-term use in healthy dogs · The FDA-approved label requires warnings about infection susceptibility and neoplastic conditions · Annual lab work recommended for dogs on long-term Apoquel

  The veterinary dermatologist consensus (petdermatologyclinic.com DACVD experience) rates Apoquel’s long-term safety positively for appropriate candidates: rapid onset, low GI side effect likelihood, and rare serious effects in dogs without contraindicated conditions. Zoetis’s own published data reports that 60% of moderate to severe atopic dermatitis cases are controlled long-term at once-daily dosing. A 2025 peer-reviewed pharmacovigilance study in the Journal of Veterinary Pharmacology and Therapeutics reviewed safety data across pre-approval and post-market phases and found the adverse event profile consistent between the two periods — primarily gastrointestinal (diarrhea, anorexia, lethargy) — consistent with the product’s known mechanism. The critical nuance: “safe for most dogs” does not mean “safe for all dogs.” The FDA-approved label specifically requires a warning that Apoquel “may increase susceptibility to infection and exacerbation of neoplastic conditions.” Dogs with a history of cancer, serious infections, or compromised immune systems face a different risk profile than healthy dogs with atopic dermatitis.
• 2
  What are the long-term side effects of Apoquel in dogs? Most common (GI): vomiting, diarrhea, decreased appetite, lethargy · Documented in label/FDA: subcutaneous and dermal masses, decreased leukocytes, decreased globulins, increased cholesterol and lipase · Serious risk: increased susceptibility to bacterial and fungal infections; worsening of existing neoplastic (cancer) conditions · Rare with long-term use in healthy dogs when monitored properly

  The Zoetis package insert lists side effects documented in clinical trials: vomiting, diarrhea, lethargy, anorexia, subcutaneous or dermal masses (unspecified), decreased leukocytes (white blood cells), decreased globulins, and increased cholesterol and lipase. innovetpet.com’s February 2026 review categorizes long-term monitoring concerns into two groups: mild adjustment symptoms (primarily gastrointestinal) and immune-related risks from JAK pathway modulation. Because Apoquel works by modulating immune signaling pathways, it can — at higher doses or in susceptible dogs — reduce the immune response more broadly than intended. The petdermatologyclinic.com DACVD notes that in humans, drugs in the same JAK inhibitor class are associated with neutropenia, anemia, thrombocytopenia, increased liver values, increased cholesterol, UTI, weight gain, and herpes zoster — though the canine dosing is significantly lower and these effects are rarely observed at therapeutic veterinary doses. The veterinary standard for long-term Apoquel management: baseline bloodwork before starting, with periodic monitoring (CBC and chemistry panel) at least annually for dogs on continuous long-term use.
• 3
  Does Apoquel cause cancer in dogs? The FDA-required label warns it “may increase susceptibility to infection and exacerbation of neoplastic conditions” — meaning it can worsen existing cancer · A 2020 peer-reviewed JAVMA cohort study (660 dogs) found no statistically significant increase in new cancer development · Apoquel should NOT be given to dogs with a known cancer history · Annual cancer screening recommended for dogs on long-term use

  This is the most commonly searched and most nuanced question about Apoquel. The honest answer has two parts. First, the FDA label is explicit: Apoquel “may increase susceptibility to infection and exacerbation of neoplastic conditions.” This warning was required based on pre-approval findings of mast cell tumors, lymphomas, and other cancers in dogs in long-term field studies. In dogs with existing but undetected cancer, Apoquel’s immune modulation can allow those existing tumors to progress more rapidly — this is the well-documented “exacerbation” risk. Second, the question of whether Apoquel causes new cancer in previously healthy dogs is less settled. A 2020 peer-reviewed cohort study published in JAVMA (660 dogs, age- and breed-matched) found a malignancy rate of 16.5% in Apoquel-treated dogs versus 12.8% in controls — a difference that was described as not statistically significant and “dose-independent” by the authors. The study’s conclusion: regular cancer screening is recommended, but evidence for Apoquel causing new malignancies in otherwise healthy dogs is not conclusive. The poison.org assessment is consistent: “Apoquel cannot be used in dogs who have a history of neoplasms” — and in dogs with cancer, “the medication did make the condition worse in some cases.”
• 4
  What is the Apoquel dosage chart for dogs by weight? FDA-approved dose: 0.4–0.6 mg/kg (0.18–0.27 mg/lb) · Initial phase: twice daily for up to 14 days · Maintenance: once daily · Tablet strengths: 3.6 mg, 5.4 mg, 16 mg · Not approved for dogs under 12 months or under 3 kg (6.6 lbs) · See complete weight-based dosage table below

  The FDA-approved dosage is 0.4 to 0.6 mg per kilogram of body weight, which equals approximately 0.18 to 0.27 mg per pound — as confirmed by GoodRx’s August 2025 veterinary review (Dr. Sarah Wooten, DVM, CVJ) and the Zoetis package insert filed with FDA’s DailyMed. Apoquel is available in three tablet strengths: 3.6 mg (marked AQ-S), 5.4 mg (marked AQ-M), and 16 mg (marked AQ-L). Your veterinarian will mix and match these strengths to reach the appropriate dose for your specific dog’s weight. The initial treatment phase is twice daily for up to 14 days — this FDA-approved duration gets itching under control rapidly; long-term twice-daily use beyond 14 days is off-label and requires specific veterinary justification. The maintenance phase is once daily indefinitely. Zoetis reports that 60% of cases are controlled at once-daily dosing; some severe cases may benefit from twice-daily long-term, which the petdermatologyclinic.com DACVD notes is off-label. The complete weight-based dosage table is provided in the section below.
• 5
  Can I give my dog 2 Apoquel a day? Twice daily is FDA-approved for the initial 14-day phase only · Long-term twice-daily use is off-label (not FDA approved beyond 14 days) · Do NOT give two doses at once to make up for a missed dose — skip the missed dose and resume the next scheduled one · Only your veterinarian should determine if extended twice-daily dosing is appropriate for your dog

  The FDA-approved dosing schedule is clearly defined: twice daily (BID) for a maximum of 14 days during the initial acute phase, followed by once daily (SID) for ongoing maintenance. innovetpet.com’s February 2026 guide specifically cautions that doubling up doses to compensate for a missed dose can lead to toxic levels — if you miss a dose, give the next one at the regularly scheduled time and continue forward without trying to catch up. The petdermatologyclinic.com DACVD explicitly states: “Apoquel is not FDA approved to use twice daily longer than 14 days. The dose range is very strict — I do not recommend going above the recommended dose due to immune suppression.” Some dogs with severe, difficult-to-control atopic dermatitis may be maintained on twice-daily dosing long-term as an off-label decision made by a veterinary dermatologist — but this is a specialist decision made with full knowledge of the individual dog’s cancer screening history and infection risk, not a self-dosing decision by the owner. GoodRx confirms: “Never give your pet extra doses or two doses at one time.”
• 6
  What happens if you stop Apoquel suddenly? Apoquel does not require a tapering schedule to discontinue safely · Stopping suddenly does not cause withdrawal symptoms · The itch will return within 24 hours of stopping — Apoquel clears the system in approximately 24 hours · Steroids can be used as a bridge if needed when stopping · The return of itching is the underlying condition returning, not a rebound effect

  Unlike steroids (prednisone, dexamethasone) which require gradual dose tapering to prevent adrenal insufficiency, Apoquel does not require a taper when discontinuing. bestiepaws.com’s January 2026 review confirms: “Apoquel clears the system in 24 hours” — both an advantage (quick assessment of efficacy; rapid discontinuation if side effects occur) and a disadvantage (daily dosing required; no protective window after missed doses). When Apoquel is stopped — for any reason — the dog’s underlying allergic condition returns, typically within 24 hours. This is not a withdrawal reaction or a rebound effect; it is simply the return of the condition Apoquel was controlling. If stopping Apoquel while investigating a diagnostic concern (possible cancer, infection, etc.), a veterinarian may bridge the dog onto a short course of steroids to manage itch while the workup proceeds. If stopping because Apoquel is no longer needed (seasonal allergy resolution, successful immunotherapy), no medical bridge is typically necessary.
• 7
  Is Apoquel hard on a dog’s kidneys? No specific kidney toxicity has been identified or documented in the FDA label, clinical trials, or the 2025 PMC pharmacovigilance review · The FDA label lists increased cholesterol and lipase (pancreatic) as laboratory changes, not kidney markers · Pre-existing kidney disease should be discussed with your vet before starting Apoquel · Routine lab monitoring (CBC + chemistry including kidney values) recommended annually

  A frequently searched concern — “Is Apoquel hard on a dog’s kidneys?” — is not directly supported by the available evidence. The Zoetis package insert and FDA’s DailyMed documentation of Apoquel do not identify specific nephrotoxicity (kidney damage) as a documented side effect or safety concern. The 2025 PMC pharmacovigilance review (Nederveld, Krautmann, Mitchell) — the most comprehensive post-market safety review published to date — similarly does not identify kidney disease as a primary adverse event category for oclacitinib. The laboratory changes documented in the FDA label are increased cholesterol and increased lipase (a pancreatic enzyme), along with decreased leukocytes and decreased globulins. Kidney function parameters (BUN, creatinine, SDMA) are not specifically flagged in the label. However, because Apoquel modulates immune function systemically and some of its side effects involve secondary infections, dogs with compromised kidney function represent a special population that warrants individual veterinary assessment — as does any medication in a dog with pre-existing organ disease. Annual bloodwork including kidney values is the standard of care for any dog on long-term daily medication.
• 8
  Can a dog stay on Apoquel for life? Yes — many dogs take Apoquel for the rest of their lives · GoodRx confirms “many dogs take the medication for the rest of their lives” · Long-term use in healthy dogs without cancer history is supported by the 2025 PMC safety review and Zoetis post-market data · Annual monitoring (bloodwork, cancer screening, infection assessment) is the standard of care · The goal is always the lowest effective dose

  GoodRx’s August 2025 veterinary guide (Dr. Sarah Wooten, DVM, CVJ) explicitly states: “Many dogs take the medication for the rest of their lives.” The veterinary consensus is that life-long Apoquel use is appropriate for dogs with chronic, recurrent atopic dermatitis who do not have contraindicated conditions (active cancer, serious infection, pregnancy, age under 12 months) and who are monitored appropriately. The petdermatologyclinic.com DACVD’s clinical experience endorses this approach with appropriate monitoring. The critical counterpoint: Apoquel controls symptoms but does not address the underlying cause of allergies. Immunotherapy (allergy shots or sublingual drops) is the only treatment that addresses the root cause — it takes 6–12 months to show effect but can reduce or eliminate the need for Apoquel over time in dogs whose allergies are primarily environmental. For seasonal allergy dogs, Apoquel can be used only during the symptomatic season, reducing total lifetime exposure. The goal should always be the lowest effective dose, periodic reassessment of whether the dose or frequency can be reduced, and regular veterinary monitoring of bloodwork and overall health.
• 9
  Is there a safer alternative to Apoquel for dogs? Cytopoint (lokivetmab injection) — monthly injection blocking IL-31, no systemic immune suppression, no cancer warning on label · Immunotherapy (allergy shots/drops) — addresses the root cause; 6–12 months for effect · Atopica (cyclosporine) — for Apoquel/Cytopoint non-responders; higher side effect profile · Steroids (prednisone) — effective short-term; not suitable long-term · Apoquel and Cytopoint can be combined for severe cases

  Cytopoint is currently the most commonly recommended alternative to Apoquel when a safer long-term profile is desired or when cancer history is present. bestiepaws.com’s January 2026 Cytopoint vs. Apoquel comparison notes a key distinction: while Apoquel’s FDA label requires explicit cancer warnings, Cytopoint’s USDA-approved biological label carries no such neoplastic warnings — though this reflects different regulatory standards (drugs vs. biologics) and less accumulated post-market data rather than confirmed cancer safety superiority. Cytopoint specifically blocks interleukin-31 (the protein directly responsible for itch signaling) as a targeted monoclonal antibody, potentially with less systemic immune impact than Apoquel’s JAK1 pathway inhibition. For dogs that do not respond adequately to either Apoquel or Cytopoint, Atopica (cyclosporine) is the next option — effective but with a higher side effect burden and requiring 4–6 weeks for full effect, versus Apoquel’s 4–24 hour onset. Immunotherapy (ASIT — allergen-specific immunotherapy) addresses the underlying immune hypersensitivity and is the only treatment that can produce lasting remission; however it requires allergy testing, a 6–12 month build-up phase, and ongoing maintenance injections or sublingual drops. Apoquel and Cytopoint can also be used together for severe, difficult-to-control cases.
• 10
  What does the FDA warning say about Apoquel? FDA-required label warning (Zoetis package insert): “May increase susceptibility to infection and exacerbation of neoplastic conditions” · FDA issued an expanded post-marketing safety communication: serious infections documented post-approval include bacterial pneumonia, deep skin infections, and disseminated fungal infections · Zoetis received an FDA warning letter for false or misleading risk presentation in promotional materials · Report adverse events: FDA MedWatch or Zoetis 1-888-963-8471

  The FDA’s oversight of Apoquel has produced several important public communications. The core label warning — required by FDA on every Apoquel package insert — states that the drug “may increase susceptibility to infection and exacerbation of neoplastic conditions.” bestiepaws.com’s November 2025 review of FDA communications notes that post-approval pharmacovigilance data has documented serious infections including bacterial pneumonia, deep skin infections, and disseminated fungal infections in dogs on Apoquel — events that align with the label warning. Additionally, poison.org documents that the FDA has issued a broader warning about the JAK inhibitor drug class in humans: “Serious side effects with other medications in this class including risk of severe heart-related events, cancer, blood clots and death.” While canine oclacitinib is significantly more selective than human JAK inhibitors, this class-level context is part of the FDA’s regulatory environment for the drug. A separate FDA warning letter was issued to Zoetis for false or misleading risk presentation in Apoquel promotional materials — indicating the company’s marketing did not always reflect the full risk profile documented in the approved label. Report adverse events at fda.gov/MedWatch or call Zoetis directly at 1-888-963-8471.

Sources: FDA NDA 141-345/DailyMed NIH (oclacitinib approval 2013; ≥12 months; 0.4–0.6 mg/kg; BID ≤14 days then SID; label warnings infection/neoplastic; tablet strengths 3.6/5.4/16 mg); PMC JVPT Nederveld Krautmann Mitchell 2025 (5-year PV surveillance; post-market consistent with pre-approval; JAK1 selective; chewable 2023); PMC JAVMA 2020 (660 dogs age-breed matched; 16.5% vs 12.8% malignancy; not statistically significant; dose-independent; regular screening); petdermatologyclinic.com DACVD (60% controlled once-daily; off-label BID long-term; dose range strict; no above recommended; rare side effects monitored); bestiepaws.com Nov 2025 / Mar 2026 (FDA warning bacterial pneumonia fungal; neoplastic findings label; FDA warning letter Zoetis; Apoquel clears 24 hrs; stopping no taper; 1-888-963-8471); GoodRx Aug 2025 Dr. Wooten DVM CVJ (0.18–0.27 mg/lb; many dogs lifetime; skip missed dose no double); poison.org (FDA JAK class heart/cancer/clots/death warning; neoplasm contraindication; not breeding/pregnant); vetlens.com Apr 2026 (4-24 hr onset; JAK pathway; vs. steroids; vs. Cytopoint; vs. immunotherapy); innovetpet.com Feb 2026 (tablet strengths; immune modulation mites; don’t double dose toxic); pethelpful.com Mar 2026 (Cytopoint; Atopica; alternatives; patent until 2026); ASPCA Poison Control (888-426-4435)

Sources: FDA (2013 approval; 2023 chewable; ≥12 months; label warnings); PMC JVPT 2025 (long-term safety profile); GoodRx Aug 2025 (lifetime use statement); vetlens.com Apr 2026 (onset); Zoetis package insert (contraindications)

The FDA-approved dose is 0.4–0.6 mg/kg body weight (approximately 0.18–0.27 mg per pound). Your veterinarian will select the appropriate tablet strength(s) from the three available: 3.6 mg, 5.4 mg, and 16 mg. These can be combined to reach the correct dose. This table is for reference only — always follow your veterinarian’s specific dosing instructions, which may differ based on your dog’s individual health needs.

⚠️ For reference only. Actual dosing determined by your veterinarian. Minimum weight: 3 kg (6.6 lbs). Not approved for dogs under 12 months of age. Twice-daily dosing may be used for the first 14 days only (per FDA label). Source: FDA NDA 141-345; Zoetis package insert; GoodRx Aug 2025 Dr. Wooten DVM CVJ; DailyMed NIH.

Sources: bestiepaws.com Jan 2026 (Cytopoint vs. Apoquel comparison; IL-31 targeting; no neoplastic warning Cytopoint; different regulatory pathways); vetlens.com Apr 2026 (vs. steroids; vs. Cytopoint; vs. immunotherapy; combination use); pethelpful.com Mar 2026 (Atopica/cyclosporine; Cytopoint efficacy reduction frequent use; steroid alternative); petdermatologyclinic.com DACVD (60-70% immunotherapy; seasonal use strategy; combinations)

Sources: FDA label / Zoetis package insert (cancer/infection/age/weight/breeding contraindications; lab changes CBC globulins cholesterol lipase); petdermatologyclinic.com DACVD (baseline + annual bloodwork; annual cancer screening; monitor infections); bestiepaws.com Nov 2025 (bacterial pneumonia fungal deep skin infections post-market; chewable tablet palatability); Lister Basile Wegenast JVECC Apr 2025 (overdose: immune suppression GI skin enlarged lymph nodes); poison.org (contraindications; neoplasm; breeding; pregnancy); ASPCA Poison Control (888-426-4435); Zoetis adverse events (1-888-963-8471); FDA MedWatch (fda.gov/MedWatch)